Cargando…
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
RATIONALE & OBJECTIVE: The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of these agents. The literature on the nephrotoxicity of...
Autores principales: | Mamlouk, Omar, Selamet, Umut, Machado, Shana, Abdelrahim, Maen, Glass, William F., Tchakarov, Amanda, Gaber, Lillian, Lahoti, Amit, Workeneh, Biruh, Chen, Sheldon, Lin, Jamie, Abdel-Wahab, Noha, Tayar, Jean, Lu, Huifang, Suarez-Almazor, Maria, Tannir, Nizar, Yee, Cassian, Diab, Adi, Abudayyeh, Ala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322290/ https://www.ncbi.nlm.nih.gov/pubmed/30612580 http://dx.doi.org/10.1186/s40425-018-0478-8 |
Ejemplares similares
-
Checkpoint inhibitor-related renal vasculitis and use of rituximab
por: Mamlouk, Omar, et al.
Publicado: (2020) -
Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis
por: Lin, Jamie S., et al.
Publicado: (2021) -
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
por: Abdelrahim, Maen, et al.
Publicado: (2021) -
Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
por: Parvathareddy, Vishnupriyadevi, et al.
Publicado: (2023) -
Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)